Facts of Biktarvy
BIKTARVY® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use
Initial U.S. Approval: 2018
Generic Name: bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate
Company: Gilead Sciences
Mechanism of Action: HIV-1 integrase inhibitor; HIV-1 nucleoside reverse transcriptase inhibitor (NRTI)
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
What BIKTARVY vedotin is?
BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of
treatment failure and no known substitutions associated with resistance to the individual components of BIKTARVY. Biktarvy is an example of a combination drug that can be taken as a complete regimen for treatment of the human immunodeficiency virus.
What Bictegravir/emtricitabine/tenofovir alafenamide is?
Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed dose combination drug for the treatment of HIV/AIDS. It contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide. It was approved for use in the United States in February 2018. It was approved for use in the European Union in June 2018.